Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed the day trading at $42.18 down -2.27% from the previous closing price of $43.16. In other words, the price has decreased by -$0.98 from its previous closing price. On the day, 1324462 shares were traded.
Ratios:
For a better understanding of IONS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.83 and its Current Ratio is at 5.90. In the meantime, Its Debt-to-Equity ratio is 5.09 whereas as Long-Term Debt/Eq ratio is at 4.95.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on January 02, 2024, Upgraded its rating to Buy and sets its target price to $62 from $52 previously.
On October 23, 2023, BofA Securities Upgraded its rating to Neutral which previously was Underperform and also upped its target price recommendation from $33 to $52.
On September 29, 2023, Raymond James started tracking the stock assigning a Strong Buy rating and target price of $63.Raymond James initiated its Strong Buy rating on September 29, 2023, with a $63 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 16 ’24 when Monia Brett P sold 387 shares for $44.49 per share. The transaction valued at 17,219 led to the insider holds 173,751 shares of the business.
Monia Brett P sold 23,501 shares of IONS for $1,160,303 on Feb 02 ’24. The Chief Executive Officer now owns 174,138 shares after completing the transaction at $49.37 per share. On Feb 02 ’24, another insider, Cadoret-Manier Onaiza, who serves as the EVP, Chf GL Pdt Str & Oper Ofc of the company, sold 2,125 shares for $49.60 each. As a result, the insider received 105,404 and left with 35,825 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 6.15B and an Enterprise Value of 5.27B. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.80 while its Price-to-Book (P/B) ratio in mrq is 15.74. Its current Enterprise Value per Revenue stands at 6.70 whereas that against EBITDA is -22.36.
Stock Price History:
Over the past 52 weeks, IONS has reached a high of $54.44, while it has fallen to a 52-week low of $32.69. The 50-Day Moving Average of the stock is 48.47, while the 200-Day Moving Average is calculated to be 45.20.
Shares Statistics:
Over the past 3-months, IONS traded about 1.25M shares per day on average, while over the past 10 days, IONS traded about 1.08M shares per day. A total of 144.34M shares are outstanding, with a floating share count of 133.95M. Insiders hold about 8.10% of the company’s shares, while institutions hold 97.26% stake in the company. Shares short for IONS as of Feb 29, 2024 were 9.11M with a Short Ratio of 7.31, compared to 8.45M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.25% and a Short% of Float of 7.38%.
Earnings Estimates
Current recommendations for the stock of the company come from 14 analysts. On average, analysts expect EPS of -$1.03 for the current quarter, with a high estimate of -$0.62 and a low estimate of -$1.4, while EPS last year was -$0.87. The consensus estimate for the next quarter is -$1.05, with high estimates of -$0.6 and low estimates of -$1.36.
Analysts are recommending an EPS of between -$3.07 and -$5.32 for the fiscal current year, implying an average EPS of -$3.99. EPS for the following year is -$3.3, with 18 analysts recommending between -$0.94 and -$5.12.
Revenue Estimates
14 analysts predict $144.06M in revenue for the current quarter. It ranges from a high estimate of $212.3M to a low estimate of $114.5M. As of the current estimate, Ionis Pharmaceuticals Inc’s year-ago sales were $128.12M, an estimated increase of 12.40% from the year-ago figure. For the next quarter, 14 analysts are estimating revenue of $145.14M, a decrease of -22.80% less than the figure of $12.40% in the same quarter last year. There is a high estimate of $177.72M for the next quarter, whereas the lowest estimate is $126.56M.
A total of 22 analysts have provided revenue estimates for IONS’s current fiscal year. The highest revenue estimate was $748M, while the lowest revenue estimate was $580.7M, resulting in an average revenue estimate of $633.44M. In the same quarter a year ago, actual revenue was $787.65M, down -19.60% from the average estimate. Based on 20 analysts’ estimates, the company’s revenue will be $772.62M in the next fiscal year. The high estimate is $1.16B and the low estimate is $570M. The average revenue growth estimate for next year is up 22.00% from the average revenue estimate for this year.
